Bioklinika - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 2,522,964 | 3,309,684 | 3,800,405 | 5,394,155 | 6,848,717 | 8,348,069 | 9,174,637 | 11,463,681 |
| Profit before tax | 75,402 | 187,952 | 525,421 | 634,728 | 793,391 | 808,128 | 936,376 | 1,317,897 |
| Net profit | 64,673 | 155,452 | 446,698 | 534,638 | 693,770 | 721,999 | 786,348 | 1,116,771 |
| Equity | 285,580 | 441,032 | 770,030 | 1,303,464 | 1,950,176 | 2,189,823 | 2,976,171 | 3,739,942 |
| Liabilities | 157,305 | 130,812 | 276,874 | 463,768 | 499,818 | 1,033,592 | 854,594 | 782,587 |
| Non-current assets | 104,853 | 103,698 | 240,093 | 292,646 | 500,802 | 973,284 | 1,086,342 | 1,071,969 |
| Current assets | 338,032 | 468,146 | 806,811 | 1,474,586 | 1,949,592 | 2,253,909 | 2,747,534 | 3,453,004 |
| Total assets | 442,885 | 571,844 | 1,046,904 | 1,767,232 | 2,450,394 | 3,227,193 | 3,833,876 | 4,524,973 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 1,469,511 | 1,672,938 | 2,206,076 |
| Social insurance contributions | - | - | - | - | - | 600,906 | 644,266 | 769,535 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +40.0% | +31.2% | +14.8% | +41.9% | +27.0% | +21.9% | +9.9% | +24.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 14.6% | 27.2% | 42.7% | 30.3% | 28.3% | 22.4% | 20.5% | 24.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 22.6% | 35.2% | 58.0% | 41.0% | 35.6% | 33.0% | 26.4% | 29.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.6% | 4.7% | 11.8% | 9.9% | 10.1% | 8.6% | 8.6% | 9.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.0% | 5.7% | 13.8% | 11.8% | 11.6% | 9.7% | 10.2% | 11.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.6 | 0.3 | 0.4 | 0.4 | 0.3 | 0.5 | 0.3 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 27,827 | 34,004 | 37,350 | 48,198 | 56,523 | 64,464 | 68,425 | 82,770 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Bioklinika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-11-18 | 2025-11-19 | 1329.71 |
| 2025-08-28 | 2025-08-29 | 408.53 |
| 2025-08-19 | 2025-08-21 | 408.53 |
Bioklinika - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Bioklinika, UAB (code 302434849) is a Private Limited Liability Company engaged in medical specialists activities. In the latest financial year, 2025, the company generated revenue of €11.46M, up 24.9% year on year and 37.3% over two years. Net profit reached €1.12M, compared with €786.3K in 2024 and €722.0K in 2023, showing a steady upward trend. Profit margin improved to 9.7% in 2025 from 8.6% in both 2023 and 2024. The balance sheet also strengthened: total assets increased to €4.52M, equity to €3.74M, and liabilities remained moderate at €782.6K. The equity ratio was 82.7%, with debt-to-equity at 0.21. Return on equity stood at 29.9% and return on assets at 24.7%, supported by asset turnover of 2.53x. Revenue per employee was €83.1K, while profit per employee was €8.1K. Overall, the company showed growth in turnover, profitability, and balance sheet strength across 2023 to 2025.